Home

Teleflex has announced the first patient enrolment in a clinical study that is intended to demonstrate the safety of the Manta vascular closure device using ultrasound guidance, without dependence on preprocedural depth locator measurements. The study will enroll patients undergoing elective transcatheter aortic valve implantation (TAVI) procedures with planned percutaneous femoral arterial access.

Enrolling up to 150 patients in up to 15 investigational sites across the USA and Canada, the MANTA Ultra study is a prospective, multicentre, single-arm trial employing the primary safety endpoint of any large bore access-site related Valve Academic Research Consortium-2 (VARC-2) major vascular complication within 30 days (adapted from VARC-2 Criteria). The occurrence of access site complications is known to be associated with higher rates of morbidity and mortality and increased costs associated with prolonged length of stay.

The practice of ultrasound-guided access has been associated with a reduced risk of major and minor access site vascular complications, as well as reduced risk of life threatening, major, and minor access site bleed complications. Teleflex is committed to exploring whether the known benefits of ultrasound-guided access will translate to ultrasound-guided closure, resulting in safe Manta device deployment, the company said in a press release.

The principal investigators of the study include David A Wood (University of British Columbia Centre for Cardiovascular Innovation, Vancouver, Canada) and Vijay S Iyer (University of Buffalo, Buffalo, USA).

“We are excited to embark on the Teleflex MANTA Ultra study,” said Wood. “We expect the study results to show that the use of ultrasound further aids in avoiding Manta device deployment complications attributed to anchor malpositioning by providing direct visualisation of the closure process.”

With visualisation of the access site during Manta device deployment, the study intends to demonstrate that ultrasound allows for precise deployment and positive positioning of the Manta device anchor within the vessel. This approach, if proven effective, will allow the Manta device to be used in clinical scenarios where the baseline arterial depth is not measured, or may have changed intraoperatively or postoperatively. Manta device ultrasound-guided closure is intended to be an alternative method to the conventional pre-procedural depth locator measurement technique that can provide additional procedural flexibility to operators.

In addition to the primary safety endpoint, the study will employ a secondary endpoint of any large bore access-site related VARC-2 minor vascular complication within 30 days (adapted from VARC-2 criteria) and secondary effectiveness endpoints that include time to haemostasis, technical success, ambulation success, time to ambulation, treatment success and procedure time—all with 30-day and 12-month follow-up timepoints.

Source CardiovascularNews

Duc Tin CLinic

Chia sẽ qua facebook bài: First patients enrolled in Manta Ultra vascular closure device study

Chia sẽ qua google bài: First patients enrolled in Manta Ultra vascular closure device study

Chia sẽ qua twitter bài: First patients enrolled in Manta Ultra vascular closure device study

Chia sẽ qua MySpace bài: First patients enrolled in Manta Ultra vascular closure device study

Chia sẽ qua LinkedIn bài: First patients enrolled in Manta Ultra vascular closure device study

Chia sẽ qua stumbleupon bài: First patients enrolled in Manta Ultra vascular closure device study

Chia sẽ qua icio bài: First patients enrolled in Manta Ultra vascular closure device study

Chia sẽ qua digg bài: First patients enrolled in Manta Ultra vascular closure device study

Chia sẽ qua yahoo bài: First patients enrolled in Manta Ultra vascular closure device study

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.